DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Insider and Institutional Ownership
10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 6.5% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares DiaMedica Therapeutics and Agenus”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DiaMedica Therapeutics | N/A | N/A | -$32.77 million | ($0.72) | -9.38 |
| Agenus | $132.69 million | 2.65 | $120,000.00 | $2.58 | 3.03 |
Agenus has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
DiaMedica Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
Profitability
This table compares DiaMedica Therapeutics and Agenus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DiaMedica Therapeutics | N/A | -77.76% | -69.43% |
| Agenus | 69.33% | -47.68% | 57.73% |
Analyst Recommendations
This is a summary of current recommendations for DiaMedica Therapeutics and Agenus, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DiaMedica Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
| Agenus | 1 | 1 | 2 | 0 | 2.25 |
DiaMedica Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 77.78%. Agenus has a consensus price target of $19.50, indicating a potential upside of 149.68%. Given Agenus’ higher possible upside, analysts plainly believe Agenus is more favorable than DiaMedica Therapeutics.
Summary
Agenus beats DiaMedica Therapeutics on 11 of the 13 factors compared between the two stocks.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
About Agenus
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
